Cooper Cos Inc Dossier - Source-backed chat

Cooper Cos Inc

COONASDAQ

SectorHealth Care

IndustryHealth Care Supplies

Beta (adjusted)0.88

Intrinsic Value $102.29median of 6 methods · middle span $85-$119based on filings through 31 Jul 2026

Market Price $57.41Price as of 1 Oct 2026

Significantly undervaluedIntrinsic value is 78% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

marker beyond scale (+78%)

Data confidence Sign in to view data confidence

Market Cap $10.9B

Enterprise Value $13.3B

Shares Outstanding 194.6M diluted

Moat Rating None

Last ex-dividend26 Jul 2023

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

CooperCompanies entered the second half of fiscal 2026 with record quarterly revenue, 5% organic growth, a 27% non-GAAP operating margin, and strong growth in fertility products. These positives are balanced by slower CooperVision growth, Asia-Pacific weakness, material recall-related litigation charges, and uncertainty around the formal strategic review. A Hold rating is appropriate pending the fiscal third-quarter update and greater clarity on the review.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets14 analysts · as of 18 Aug 2026

Low · most bearish analyst$66.00

Mean target$81.50

High · most bullish analyst$92.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$66.0020%

Organic growth falls below guidance as CooperVision weakness broadens, tariff or operating costs pressure margins, additional product-related liabilities emerge, or the strategic review fails to unlock value while creating distraction and execution costs.

Base CaseCentral scenario

$81.5055%

Matches the consensus mean

Organic growth remains within the 3.5%-4.5% fiscal 2026 guidance range, non-GAAP margins retain most of the second-quarter improvement, free cash flow progresses toward the fiscal 2026-2028 objective, and the strategic review remains unresolved or produces only incremental changes.

Bull CaseUpside scenario

$92.0025%

Execution exceeds the upper end of fiscal 2026 organic-growth guidance, CooperVision's specialty-lens mix sustains growth, fertility remains a double-digit contributor, operating efficiencies endure, and the strategic review produces a value-enhancing transaction or sharper capital allocation.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Second-quarter fiscal 2026 revenue reached a record $1.082 billion, increasing 8% as reported and 5% organically.
Second-quarter non-GAAP operating margin expanded 260 basis points year over year to 27%, while non-GAAP diluted EPS increased 26% to $1.21.
CooperSurgical grew 6% organically, including 10% organic growth in fertility, while management reaffirmed a cumulative free-cash-flow objective exceeding $2.2 billion for fiscal 2026-2028.

Key Investment Risks

A $271.6 million net pre-tax recall-related litigation charge drove a second-quarter GAAP operating loss and GAAP diluted loss of $0.40 per share.
CooperVision's second-quarter organic growth was 4%, with Asia-Pacific revenue declining 6% in constant currency and organically.
The strategic review covers businesses, corporate structure, operations, and capital allocation but has no announced completion timeline or assured transaction outcome.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.